



Dear School Nurse,

As you may know, EPIDIOLEX® (cannabidiol) was approved for use in the United States by the FDA in June 2018, and until recently, was designated as a Schedule V substance. As of April 2020, EPIDIOLEX is no longer a scheduled drug. As a first-in-class antiepileptic drug (AED), EPIDIOLEX is the first and only prescription pharmaceutical formulation of highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the “high” associated with marijuana.

EPIDIOLEX can only be prescribed by physicians and other licensed healthcare prescribers, and prescriptions are filled by specialty pharmacies and licensed pharmacists. It is prescribed and administered just like any other prescription AED used in the treatment of epilepsy.

As of 2018, it is the position of the National Association of School Nurses (NASN) that FDA-approved cannabis/marijuana medications, like EPIDIOLEX, be allowed in school settings. If you would like to review the full position brief, you can access it here: <https://www.nasn.org/advocacy/professional-practice-documents/positionbriefs/pb-cannabis>.

Additionally, “Seizure Safe/Smart Schools” legislation is underway in a growing number of states. One component of the model bill is the requirement that school districts ensure that students with epilepsy have access to their FDA-approved prescribed medications. More information is available on this legislation at: <http://advocacy.epilepsy.com/seizuresafeschools>

New medications can understandably raise questions. We thank you for your understanding to help ensure that any child who is prescribed EPIDIOLEX by their healthcare provider may continue to receive uninterrupted treatment.

Sincerely,

Greenwich Biosciences, Inc.

**For more information on EPIDIOLEX, please visit [EPIDIOLEX.com](http://EPIDIOLEX.com) and refer to the EPIDIOLEX full Prescribing Information, Medication Guide, and Instructions for Use.**

You are encouraged to report side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch), or call **1-800-FDA-1088**. You may also contact Greenwich Biosciences at **1-833-424-6724 (1-833-GBIOSCI)**.